查看文章

Glioblastoma (GBM) is a highly aggressive and malignant brain tumor. Despite aggressive treatment, GBM has a poor prognosis, and it is difficult to eliminate using current treatment strategy. Moreover, recurrence is a major challenge.

To develop glioma model, we performed intracranial injection of CT2A and SB28 mouse glioma cells. ZIKV injection was given intratumorally 7 days post tumor implantation. Four doses of anti-siglec-15 and anti-PD1 injection were given intraperitonially.

We are developing Zika virus as a therapy for GBM. previously we showed ZIKV significantly increases survival in multiple syngeneic glioma mouse models. Like other oncolytic therapies, it generates a potent, anti-tumor CD8⁺ T-cell response. Post-ZIKV, we observe a 32-fold increase in myeloid cells in the GBM microenvironment. Siglec-15 is a novel myeloid immune checkpoint in cancer, which …